The results of comparison of other indices are shown in Table 10-12
Simethicone: Helps break up gas bubbles in the stomach
Across major trials, GLP-1 receptor agonists have produced sustained weight loss, sustained improvements in glycemic control, and reductions in major cardiovascular events in patients with metabolic risk
Participants in the semaglutide group achieved a weight loss of at least 5%, 10%, or 15%, and improvements in secondary endpoints, such as waist circumference, blood pressure, and lipid levels, compared to the placebo group
Until peer-reviewed studies validate its effectiveness and safety , patients must approach the treatment with cautious optimism